Keros Therapeutics, Takeda in Elritercept Licensing Pact

Dow Jones2024-12-03

By Colin Kellaher

Keros Therapeutics has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate.

Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for an upfront payment of $200 million.

Elritercept is in late-stage development for the treatment of anemia associated with certain blood cancers, including myelodysplastic syndromes and myelofibrosis.

Keros, a Lexington, Mass., clinical-stage biopharmaceutical company, said it is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion, along with royalties on product sales.

Takeda said the addition of elritercept bolsters its oncology pipeline and introduces a potential future growth driver for the Osaka-based drugmaker.

Elritercept is a potential rival to Bristol Myers Squibb's Reblozyl, which generated sales of nearly $1.23 billion during the first nine months of 2023.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 03, 2024 08:34 ET (13:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488760917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488760917","market":"fut","top_or_hot":-1,"title":"Keros Therapeutics, Takeda in Elritercept Licensing Pact","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate. \n</p>\n<p>\n  Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for an upfront payment of $200 million. \n</p>\n<p>\n  Elritercept is in late-stage development for the treatment of anemia associated with certain blood cancers, including myelodysplastic syndromes and myelofibrosis. \n</p>\n<p>\n  Keros, a Lexington, Mass., clinical-stage biopharmaceutical company, said it is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion, along with royalties on product sales. \n</p>\n<p>\n  Takeda said the addition of elritercept bolsters its oncology pipeline and introduces a potential future growth driver for the Osaka-based drugmaker. \n</p>\n<p>\n  Elritercept is a potential rival to Bristol Myers Squibb's Reblozyl, which generated sales of nearly $1.23 billion during the first nine months of 2023. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 03, 2024 08:34 ET (13:34 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keros Therapeutics, Takeda in Elritercept Licensing Pact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeros Therapeutics, Takeda in Elritercept Licensing Pact\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Keros Therapeutics has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488760917","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488760917","pubTimestamp":1733232840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Keros Therapeutics has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate.Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for an upfront payment of $200 million.Elritercept is in late-stage development for the treatment of anemia associated with certain blood cancers, including myelodysplastic syndromes and myelofibrosis.Keros, a Lexington, Mass., clinical-stage biopharmaceutical company, said it is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion, along with royalties on product sales.Takeda said the addition of elritercept bolsters its oncology pipeline and introduces a potential future growth driver for the Osaka-based drugmaker.Elritercept is a potential rival to Bristol Myers Squib","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Keros Therapeutics与武田签订Elritercept许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"KROS":0.9,"TAK":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Keros Therapeutics has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate. \n\n\n  Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for an upfront payment of $200 million. \n\n\n  Elritercept is in late-stage development for the treatment of anemia associated with certain blood cancers, including myelodysplastic syndromes and myelofibrosis. \n\n\n  Keros, a Lexington, Mass., clinical-stage biopharmaceutical company, said it is eligible to receive development, approval and commercial milestones with the potential to exceed $1.1 billion, along with royalties on product sales. \n\n\n  Takeda said the addition of elritercept bolsters its oncology pipeline and introduces a potential future growth driver for the Osaka-based drugmaker. \n\n\n  Elritercept is a potential rival to Bristol Myers Squibb's Reblozyl, which generated sales of nearly $1.23 billion during the first nine months of 2023. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 08:34 ET (13:34 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488760917"}